515 related articles for article (PubMed ID: 24735751)
21. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
[TBL] [Abstract][Full Text] [Related]
22. SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells.
Wang CT; Lin CS; Shiau CW; Chu PY; Hsiao CC; Chiang YL; Tai WT; Chen KF
J Orthop Res; 2013 Feb; 31(2):335-42. PubMed ID: 22926753
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
[TBL] [Abstract][Full Text] [Related]
24. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
25. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
26. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
27. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
28. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
Hung MH; Tai WT; Shiau CW; Chen KF
World J Gastroenterol; 2014 Nov; 20(41):15269-74. PubMed ID: 25386075
[TBL] [Abstract][Full Text] [Related]
31. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
[TBL] [Abstract][Full Text] [Related]
32. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
33. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF
Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225
[TBL] [Abstract][Full Text] [Related]
34. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
Li R; Yanjiao G; Wubin H; Yue W; Jianhua H; Huachuan Z; Rongjian S; Zhidong L
Oncotarget; 2017 Mar; 8(12):19354-19364. PubMed ID: 28423613
[TBL] [Abstract][Full Text] [Related]
35. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
[TBL] [Abstract][Full Text] [Related]
36. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
[TBL] [Abstract][Full Text] [Related]
37. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
38. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Ou DL; Lee BS; Chang YC; Lin LI; Liou JY; Hsu C; Cheng AL
PLoS One; 2013; 8(6):e66589. PubMed ID: 23818948
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]